Stefano Cascinu

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Florian Lordick, Fátima Carneiro, Stefano Cascinu et al. · Annals of Oncology · 2022 · 1.2K citations · Full text

Esophagus, Gastrointestinal Oncology, Medicine +7

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim et al. · The Lancet Oncology · 2014 · 459 citations · Full text

Oncology, Chemotherapy-refractory Wild-type Kras, Colorectal Cancer +9

Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Stefano Cascinu, Vincenzo Catalano, L. Cordella et al. · Journal of Clinical Oncology · 2002 · 415 citations

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 402 citations · Full text